Company: TDBCP
Filing Date: 2025-06-11
Form Type: 424B2
Source: 0001140361-25-022196
Chunk: 12

Company: TORONTO DOMINION BANK
Filing Date: 2025-06-11
Form: 424B2
Chunk 12
---
 listed on the NYSE Arca under ticker symbol “XBI”. In making your investment decision you should review the prospectus related to the Underlying Fund. Information from outside sources including any other website referenced in this section, is not incorporated by reference in, and should not be considered part of, this document or any document incorporated herein by reference. We have not undertaken an independent review or due diligence of any publicly available information with respect to the Underlying Fund or the Underlying Index.

| Accelerated Return Notes® | TS-9 |

| Accelerated Return Notes®                           
 Linked to the SPDR®S&P®Biotech ETF due August, 2026 |

Historical Data The following graph shows the daily historical performance of the Underlying Fund on its primary exchange in the period from January 1, 2015 through June 6, 2025. We obtained this historical data from Bloomberg L.P. We have not independently verified the accuracy or completeness of the information obtained from Bloomberg L.P. On June 6, 2025 , the Closing Market Price of the Underlying Fund was $84.26. The graph below may have been adjusted to reflect certain corporate actions such as stock splits and reverse stock splits. Historical Performance of the Underlying Fund This historical data on the Underlying Fund is not necessarily indicative of the future performance of the Underlying Fund or what the value of the notes may be. Any historical upward or downward trend in the price per share of the Underlying Fund during any period set forth above is not an indication that the price per share of the Underlying Fund is more or less likely to increase or decrease at any time over the term of the notes. Before investing in the notes, you should consult publicly available sources for the prices and trading patterns of the Underlying Fund.

| Accelerated Return Notes® | TS-10 |

| Accelerated Return Notes®                           
 Linked to the SPDR®S&P®Biotech ETF due August, 2026 |

Supplement to the Plan of Distribution (Conflicts of Interest) Under our distribution agreement, we have appointed TDS, an affiliate of TD, and BofAS as agents for the sale of the notes. TDS will purchase the notes from us, and BofAS will purchase the notes from TDS, each at the public offering price less the indicated underwriting discount indicated on the cover hereof MLPF&S will purchase the notes from BofAS for resale, and will receive a selling concession in connection with the sale of the notes in